Robert Barrow, Chief Executive Officer at Definium Therapeutics, Inc. (DFTX), sold 29,208 shares at $45.03 ($1.3M) on 2026-06-25, disclosed to the SEC on 2026-06-26.
Scheduled sale ($1.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| DFTX | SELL | 2026-03-26 | $451K | — | Filing → |
| MNMD | SELL | 2025-12-29 | $678K | — | Filing → |
| MNMD | SELL | 2025-09-26 | $504K | — | Filing → |